Analysts Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Price Target at $41.13
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month […]
More Stories
Manhattan Bridge Capital (NASDAQ:LOAN) Coverage Initiated at StockNews.com
Analysts at StockNews.com started coverage on shares of Manhattan Bridge Capital (NASDAQ:LOAN – Get Free Report) in a report issued...
Hardeep Gulati Sells 29,750 Shares of PowerSchool Holdings, Inc. (NYSE:PWSC) Stock
PowerSchool Holdings, Inc. (NYSE:PWSC – Get Free Report) CEO Hardeep Gulati sold 29,750 shares of the company’s stock in a...
Morgan Stanley Boosts MercadoLibre (NASDAQ:MELI) Price Target to $2,500.00
MercadoLibre (NASDAQ:MELI – Get Free Report) had its target price boosted by equities researchers at Morgan Stanley from $2,175.00 to...
Korro Bio’s (KRRO) Outperform Rating Reiterated at Royal Bank of Canada
Royal Bank of Canada reaffirmed their outperform rating on shares of Korro Bio (NASDAQ:KRRO – Free Report) in a report...
Heidrick & Struggles International’s (HSII) “Outperform” Rating Reaffirmed at Barrington Research
Heidrick & Struggles International (NASDAQ:HSII – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities research analysts at...
StockNews.com Upgrades REGENXBIO (NASDAQ:RGNX) to “Hold”
REGENXBIO (NASDAQ:RGNX – Get Free Report) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold”...